HER3 Assay Portfolio Service

With the aid of our advanced platform and extensive experience in tumor marker assay discovery, Creative Biolabs is dedicated to developing one-stop HER3 assay portfolio services, which will help our customers meet their research needs.

Tumor Target HER3

HER3 is a member of the human epidermal growth factor receptor (HER) family which includes HER1/EGFR/erbB1, HER2/erbB2, and HER4/erbB4. HER family members share a common molecular structure consisting of an extracellular domain (ECD), a transmembrane domain, an intracellular domain with tyrosine kinase (TK) activity, and a c-terminal tail. As a special member of the HER family, HER3 has little or no intrinsic tyrosine kinase activity, while it usually forms heterodimers with other receptor tyrosine kinases (RTKs) to activate oncogenic signaling in cancer cells.

HER3 overexpression is relevant to several tumor types including breast, ovarian, prostate, gastric, lung, melanoma, colorectal, and squamous cell carcinoma. In melanoma and pancreatic carcinoma, HER3 is the preferred heterodimeric partner for EGFR. For HER2-mediated breast cancer, HER3 serves as a vital co-receptor of HER2, which expression is essential for cell survival and proliferation. What is more, several studies discovered that compensatory upregulation of HER3 accompanied by the persistent PI-3K/Akt signaling is associated with resistance to EGFR-targeted therapy.

HER3-targeted Therapies

During the last decades, several anti-HER3 therapies have exhibited anti-tumor activity in vivo and showed promise as novel cancer therapeutics. The targeted therapies against HER3 include the applications of mono-/bi-specific antibodies, CAR-T therapy, vaccines, HER3-locked nucleic acid-based RNA inhibitors, and small molecule inhibitors. The main mechanisms are as follows:

i) trapping or blocking ligand binding sites;

ii) abrogating dimerization of HER3 with other EGFR family members;

iii) triggering the internalization of the HER3 receptor to exert toxic effects for tumor cells;

iv) recruiting immune cells to kill cancer cells expressing endogenous HER3.

Comprehensive Workflow for HER3 Therapeutic Development

Required Starting Materials:

• HER3-targeting molecule.
• Cancer cell lines with known HER3 expression profiles.
• Preliminary binding or activity data.

Final Deliverables:

• Comprehensive project report.
• Raw and analyzed data files.
• Strategic recommendation for your next steps.

Publication

This publication focuses on HER3, a member of the EGFR/HER family of receptor tyrosine kinases that lacks an active kinase domain. This makes it an obligate binding partner with other receptors, particularly HER2, to regulate biological functions through the PI3K-AKT-mTOR pathway.

The paper explains that HER3 promotes tumorigenesis, tumor growth, and drug resistance in various cancers, including breast and non-small cell lung cancer. Because HER3 cannot be targeted with conventional small-molecule kinase inhibitors, pharmaceutical companies have explored other approaches, such as blocking the ligand-binding domain or extracellular domain. The review discusses the limited clinical efficiency of anti-HER3 monoclonal antibodies and bispecific antibodies, but notes the potential of HER3-directed antibody-drug conjugates, which are still in clinical trials. The article aims to expand the knowledge of HER3 signaling and aid in the development of a new generation of drugs with fewer side effects.

Fig.1 Mechanism of HER2-HER3 heterodimerization and downstream signaling in receptor tyrosine kinases.¹

Why Choose Us?

Creative Biolabs stands out for our deep scientific expertise and state-of-the-art technology, allowing us to go beyond simple binding assays to deliver true functional insights. Our team has a proven track record in addressing the unique challenges of HER3-targeted therapy, especially its role in mediating drug resistance by activating alternative signaling pathways. We leverage our knowledge of the tumor microenvironment and a variety of therapeutic modalities, from ADCs to bispecific antibodies, to provide you with the most relevant and actionable data. Our commitment to scientific rigor and customized solutions ensures that you receive data that is not only accurate but also directly applicable to advancing your therapeutic program.

Highlights:

• Biologically related: The HER3 assay portfolio services are MOA-reflective and suitable for many types of sample leads.
• Robust assays: The assays are highly reproducible and provide data on potency for therapeutic drug discovery and development.
• One-stop service: The company offers a one-stop service, from initial design and optimization to preclinical studies, with well-recorded data and organized reports.
• Organized reports: The services include well-recorded data and organized reports.

If there is any query, please contact us for more details.

Frequently Asked Questions

Customer Review

Related Services

To complement our HER3 assay portfolio, you may find these other services helpful in your drug discovery journey:

How to Contact Us

Ready to take the next step in your HER3 therapeutic project? Our team of experts is ready to assist you.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Majumder, Avisek. "HER3: toward the prognostic significance, therapeutic potential, current challenges, and future therapeutics in different types of cancer." Cells 12.21 (2023): 2517. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3390/cells12212517

For Research Use Only | Not For Clinical Use